UNSPSC 51294509: Metioxate

This classification denotes an antibiotic with the molecular formula C22H27N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 00V69U1QC7 chemically known as 2-(4-methylpiperidino)ethyl 6-ethyl-2,3,6,9-tetrahydro-3-methyl-2,9-dioxothiazolo(5,4-f)quinoline-8-carboxylate but generally known as metioxate, which bears US NIH Compound Identifier 3047729. European Medicines Agency schedules Metioxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08890MIG.

UNSPSC 51294509 Metioxate is a Commodity code that does not appear to align with the state and local procurement activity currently tagged to it. The three recent opportunities posted under this code involve naloxone (an opioid-reversal medication), safe drug deactivation systems, and generic multi-source pharmaceuticals and OTC products — none of which are metioxate, a cytotoxic chemotherapy agent used in cancer treatment. The mismatch suggests either tagging error in the source data or that metioxate procurement through state and local channels is sufficiently rare that it does not generate the recent solicitation volume needed to characterize genuine market activity under this code.

The issuing bodies pursuing pharmaceutical and medical-product procurement span state health agencies (Texas Health and Human Services Commission), multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participants), and county health departments (Seminole County, Florida). The geographic footprint includes Texas, Minnesota, Oregon, and Florida, with activity concentrated in state-level and cooperative-purchasing initiatives rather than fragmented local-government buys. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023), Texas HHS's RFI on direct-to-manufacturer pharmacy benefit programs (response due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson (response due March 26, 2026). The code shows little relevant recent activity under its nominal scope and warrants verification against actual metioxate procurement patterns before committing resources to pursuit.